Tech Firm Partners to Advance AI-Powered Support for MDs

1. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc. 
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on December 8, 2025

1. For the quoted article (published on December 8, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$2,000.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA), based in British Columbia, has partnered with two Canadian entities, the Coordinated Accessible National (CAN) Health Network and Health Cities, to advance its artificial intelligence (AI)-powered Clinical Decision Support System (CDSS), designed to help primary care physicians deliver faster, evidence-based and more efficient care, toward commercialization, according to a news release.

The federally funded CAN Health Network helps Canadian health technology companies pilot, commercialize, and scale their innovations within the national healthcare system and globally. Nonprofit organization Health Cities helps accelerate and catalyze innovation in healthcare.

Rocket Doctor AI's CDSS is initially being deployed on a small scale for a trial period with the goal of expanding it province-wide next year. To start, about 20 primary care physicians at four sites in Alberta will use the system between November 2025 and March 2026. The technology is envisaged to be rolled out in three phases, starting with AI-powered patient intake via a website-embedded chatbot, followed by real-time clinician support during visits, and ultimately integration with electronic medical records.

"This collaboration will allow Alberta's health care community to evaluate how AI can improve system efficiency and clinical decision-making in real-world settings," Dr. Dante Morra, founder and chief executive officer (CEO) of the CAN Health Network, said in the release. "By starting with intake and decision support, we can scale to support thousands of providers across the province."

Rocket Doctor AI CDSS platform is designed to help (i) reduce physician intake time (anticipated to be between 25–40%), (ii) improve patient satisfaction due to faster, clearer communication, and (iii) decrease the time clinicians spend on charting, documentation, billing, and other administrative tasks.

The healthcare tech firm's platform will be hosted in secure, Canadian data centers in accordance with Canada's Personal Information Protection and Electronic Documents Act (PIPEDA), Alberta's Health Information Act, and the U.S. Health Insurance Portability and Accountability Act (HIPAA). The modular system may be subsequently scaled to be available to Alberta's 4,400 primary care providers and beyond.

The collaboration to advance CDSS aims to provide primary care clinicians in Alberta with an integrated, AI-powered system that can analyze data from various diverse sources, automate routine tasks, and deliver real-time clinical recommendations. In so doing, the collaboration ultimately aims to relieve the strain on these providers, medical practices, and clinics caused by staffing shortages, expanding patient loads, and limited access to primary care. In the province, 1 in 5 residents lacks a family physician, and many communities must wait long periods of time for basic care, according to the Alberta Medical Association in its "State of Health Care 2025 Report."

"Our mission is to empower health care providers with tools that improve patient outcomes and restore time for meaningful patient interactions," Dr. Essam Hamza, CEO of Rocket Doctor AI, said in the release. "This collaboration will help demonstrate how AI can directly support physicians on the front lines of care."

Rocket Doctor AI, the CAN Health Network, and Health Cities entered into an agreement on Nov. 12, with a joint objective that the proposed AI-powered clinical decision support system will empower physicians to deliver higher quality care, anticipate and mitigate health issues before they  become critical, and improve overall patient outcomes.

Redefining Modern Healthcare

Rocket Doctor AI has developed physician-led, AI-powered platforms for enabling high-quality healthcare accessible and deliverable throughout the entire patient journey, the release described.

The foundation of the company's proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide. The GLM assists providers with triage, differential diagnoses, and evidence-based care planning.

John Newell of John Newell and Associates wrote that Rocket Doctor AI's stock is moving into a confirmed reversal phase from a prolonged consolidation into a confirmed reversal phase. He rates it Speculative Buy.

Alongside the GLM is Rocket Doctor Inc.'s AI-powered digital health platform and marketplace.

The company's proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices, thereby restoring their autonomy, improving efficiency, and expanding patient access to care.

In Canada, the 300-plus physicians now on this "Shopify for physicians" platform in Alberta, British Columbia, and Ontario have provided care in 700,000-plus patient visits. Of those, 97% were managed virtually, not needing a referral to in-person care, according to Rocket Doctor AI's Investor Presentation.

Rocket Doctor AI is committed to reaching underserved, rural, and remote communities in the U.S. and Canada that often lack access to family doctors and to supporting patients on Medicaid and Medicare in the U.S.

The company generates annual recurring revenue in three ways through:

1) Fees paid by physicians for every virtual appointment booked

2) Fees paid by partners, including pharmacies, allied health groups, and independent provider associations, for use of the platform, for support, and for device-enabled stations

3) Monthly fees paid by physicians for use of the platform

As outlined in its recent Q3 financials, revenue from these streams exceeds ~ CA$2 million (CA$2M) per year.

The Catalyst: 38.5% CAGR by 2030

Global AI in healthcare is a high-growth sector, expected to expand at a 38.5% compound annual growth rate between 2024 and 2030. During this period, the market is projected to septuple, reaching US$187.7 billion (US$187.7B) in size from US$26.6B, according to The Research Insights.

Growth drivers, according to Research and Markets, include increasing AI integration, advancements in human-aware AI systems, and investments from the public and private sectors. Other contributing factors, wrote Precedence Research, include the reduced costs, the greater efficiency, and the improved patient outcomes that result from the use of AI.

With a 45% or higher share, North America dominates the global AI in healthcare market, the market research firm noted. This is due to the region's superior healthcare information technology infrastructure, widespread implementation of AI and machine learning technologies, and increasing healthcare costs.

Supportive government policies and large investments, along with the presence of top tech and healthcare firms, have accelerated market growth in North America.

A Nov. 17 New York Times (TNYT) video article highlighted that it is still necessary and important for people with medical symptoms or a medical problem to connect with an actual physician or other healthcare provider and not rely solely on online AI sources like ChatGPT for medical advice.

This, in large part, is because these chatbots generally lack the ability to provide the inquirer with next steps to address their alleged medical problem or how to treat it. In a soon-to-be-published study by the University of Oxford, people were given a medical scenario and instructed to use a chatbot to diagnose it. Results showed that the chatbot diagnosed the correct condition 34.5% of the time and advised the correct course of action 44.2% of the time.

"These models are not a substitute for a doctor or a clinician," Dr. Adam Rodman, medical AI researcher at Beth Israel Deaconess Medical Center, told TNYT. "They are a beginning of that conversation."

The article pointed out that more and more people in the U.S. are turning to AI chatbots for this type of help. A recent Kaiser Family Foundation survey showed that about 1 in 6 adults aged 30 and up use them for medical info at least once per month. For adults under 30, it is about 1 in 4.

Stock Has Defined Upside Targets

¹John Newell of John Newell and Associates wrote recently that Rocket Doctor AI's stock is moving into a confirmed reversal phase from a prolonged consolidation into a confirmed reversal phase. Several indicators, including volume patterns, Fibonacci retracement support, and momentum, suggest the stock will likely reach higher and higher targets sequentially. He rates it Speculative Buy.

"For speculative investors, the stock offers a technical setup with clearly defined upside targets," Newell wrote.

Already, the stock surpassed Newell's first target price. The return to his second target price from the midday Dec. 10 price is 30%.

"Reclaiming this zone would mark a return to midcycle valuation levels and confirm a higher time frame reversal," he added.

Ownership and Share Structure²

Insider ownership of Rocket Doctor AI totals 4.63%. Retail investors hold the rest.

Rocket Doctor AI has 85.26 million shares outstanding. Its market cap is CA$68.21M. Its 52-week range is CA$0.33–0.98/share.